{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-023179","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.133668+00:00","generated_at":"2026-06-02T00:32:03.324052+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Ocugen Q1 net loss $0.05/share, cash $26.4M; OCU400 Phase 3 underway","bullets":["Net loss $0.05/share for Q1 2024 vs $0.08 loss in Q1 2023; total operating expenses $13.2M, down 29% YoY.","Cash and cash equivalents $26.4M at March 31, 2024, versus $39.5M at December 31, 2023.","OCU400 Phase 3 liMeliGhT trial cleared by FDA; dosing begins Q2 2024; EMA supports MAA submission.","OCU410 (dAMD) cohort 2 dosing complete; Phase 2 expansion expected Q3 2024. OCU410ST cohort 2 enrollment initiated.","NeoCart GMP facility renovated; Phase 3 contingent on funding. OCU500 IND planned mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-023179","json":"https://secwatch.observer/filing/0001628280-24-023179.json","markdown":"https://secwatch.observer/filing/0001628280-24-023179.md","text":"https://secwatch.observer/filing/0001628280-24-023179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/ocgn-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:32:03.324052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8209aa53cb5483405264cc14f2fcd238dda24b90","claim":"Ocugen, Inc. reported first quarter 2024 results: net income a $0.05 net loss per common share, EPS a $0.05 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Net income","value":"a $0.05 net loss per common share"},{"label":"EPS","value":"a $0.05 net loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c6e54e4e456928ba59fc70e3cb677068c48154e3","claim":"Ocugen, Inc. reported three months ended March 31, 2024 results: net income Total operating expenses for the three months ended March 31, 2024 were $13.2 million, EPS a $0.05 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Net income","value":"Total operating expenses for the three months ended March 31, 2024 were $13.2 million"},{"label":"EPS","value":"a $0.05 net loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}